HIPEC with oxaliplatin in the treatment of peritoneal carcinomatosis of colorectal origin.
Elias
D
D
Institut Gustave Roussy, Départment de Chirurgie, Villejuif, France. elias@igr.fr
Pocard
M
M
Goere
D
D
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D015179:Colorectal Neoplasms / Q000473:pathology* / Q000601:surgery; D004358:Drug Therapy / Q000379:methods; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D007263:Infusions, Parenteral / Q000379:methods*; D000077146:Irinotecan; D008297:Male; D009944:Organoplatinum Compounds / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000077150:Oxaliplatin; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D015996:Survival Rate; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000077146:Irinotecan; D002166:Camptothecin